(1)
Rahim, N. Bispecific CAR-T Vs. BCMA-Specific CAR-T: Advancing Treatment for Relapsed Refractory Multiple Myeloma. HSET 2025, 153, 42-47. https://doi.org/10.54097/wvmnsh51.